Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Revolution Medicines to Participate in November 2025 Investor Conferences - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( NASDAQ:RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Kailera Therapeutics Appoints Frank Clyburn to Board of Directors
WALTHAM, Mass. and SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the appointment of Frank ...
Why Is Tango Therapeutics Stock Falling Today - Tango Therapeutics ( NASDAQ:TNGX )
Tango Therapeutics Inc. ( NASDAQ:TNGX ) revealed data from its ongoing Phase 1/2 study of vopimetostat ( TNG462 ) in patients with MTAP-deleted cancers. As of September 1, 2025, 179 patients were enrolled across all histologies, with 154 at active doses ( 200 mg and above ) .
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat ( TNG462 ) in Patients with MTAP-deleted Cancers - Tango Therapeutics ( NASDAQ:TNGX )
- 2L MTAP-del pancreatic cancer median progression free survival ( mPFS ) 7.2 months with an objective response rate ( ORR ) of 25% - - Combination studies with RAS ( ON ) inhibitors ongoing, data anticipated 2026 -
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS ( OFF ) G12C Inhibitor
REDWOOD CITY, Calif., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS ( ON ) G12C-selective ...
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - American Express ( NYSE:AXP ) , AppFolio ( NASDAQ:APPF )
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Friday.
FDA Unveils Fast-Track Drugs to Slash Review Times - Disc Medicine ( NASDAQ:IRON )
The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times ...
Revolution Medicines Awarded Voucher for Daraxonrasib ( RMC-6236 ) Under FDA Commissioner's National Priority Voucher Pilot Program - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( NASDAQ:RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S.
Revolution Medicines Awarded Voucher for Daraxonrasib ( RMC-6236 ) Under FDA Commissioner's National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S.
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
REDWOOD CITY, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role ...
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Revolution Medicines ( NASDAQ:RVMD )
In 2L RAS mutant PDAC, daraxonrasib showed 35% ORR and 92% disease control with a median survival of over 13 months. First-line trials showed 47% ORR and 89% disease control, with most patients still on treatment at data cutoff. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Aon ( NYSE:AON ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Fargo raised W. P. Carey Inc. WPC price target from $68 to $72.
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - Revolution Medicines ( NASDAQ:RVMD )
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability ...
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Exodus Movement ( AMEX:EXOD ) , ICU Medical ( NASDAQ:ICUI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo initiated coverage on Revolution Medicines, Inc.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Tango ( TNGX ) Q2 Revenue Drops 52%
Tango Therapeutics ( NASDAQ:TNGX ) , a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst ...
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
- First patient dosed in combination trial of TNG462 and Revolution Medicines RAS ( ON ) inhibitors ...
Wall Street Analysts Believe Revolution Medicines ( RVMD ) Could Rally 90.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - Revolution Medicines ( NASDAQ:RVMD )
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - GitLab ( NASDAQ:GTLB ) , Amrize ( NYSE:AMRZ )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Derek Podhaizer initiated coverage on Select Water Solutions, Inc.
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates
REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology ...
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors - Summit Therapeutics ( NASDAQ:SMMT ) , Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. ( Nasdaq: SMMT ) , a biopharmaceutical ...
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and ...
Revolution Medicines To Advance Lead Cancer Drug With Funding Worth $2B - Royalty Pharma ( NASDAQ:RPRX ) , Revolution Medicines ( NASDAQ:RVMD )
The deal includes up to $1.25 billion in royalties and $750M in corporate debt for daraxonrasib. Royalty rate on sales over $8 billion drops to zero under 15-year funding agreement. See how Matt Maley is positioning for global volatility, sector rotations, and macro shifts-live this Wednesday, ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma ( NASDAQ:RPRX )
Up to $1.25 billion ( $250 million upfront ) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS ( ON ) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - Revolution Medicines ( NASDAQ:RVMD )
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder value
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
REDWOOD CITY, Calif., June 23, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S.
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected ...
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - AppLovin ( NASDAQ:APP ) , Alvotech ( NASDAQ:ALVO )
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Thursday. Shares of Groupon, Inc. GRPN rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results.
TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER
Reality Star Joan Vassos, "Star Trek" Team, Days of our Lives' Martha Madison & Cast Members and Lisa Niemi Swayze Take Steps to Raise Funds and Awareness for Pancreatic Cancer
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - Revolution Medicines ( NASDAQ:RVMD )
Zoldonrasib showed a 61% objective response rate and 89% disease control rate in NSCLC patients at 1200 mg QD. Most treatment-related side effects were mild, with a 98% mean dose intensity and no dose-limiting toxicities observed. Don't face extreme market conditions unprepared.
Revolution Medicines Presents Initial Data from Zoldonrasib ( RMC-9805 ) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., April 27, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc.
Revolution Medicines Presents Initial Data from Zoldonrasib ( RMC-9805 ) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Zoldonrasib, a RAS ( ON ) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS ( ON ) G12D-selective inhibitor, demonstrated acceptable ...
Revolution Medicines to Participate in April 2025 Investor Conferences - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., March 31, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Does Revolution Medicines ( RVMD ) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Keros Therapeutics ( KROS ) Soars 5.1%: Is Further Upside Left in the Stock?
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines ( RVMD ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Revolution Medicines (RVMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Revolution Medicines ( RVMD ) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is John Hancock Multifactor Small Cap ETF ( JHSC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million ...
Should John Hancock Multifactor Small Cap ETF ( JHSC ) Be on Your Investing Radar?
Style Box ETF report for ...
Top 3 Health Care Stocks That Could Blast Off In December - Elanco Animal Health ( NYSE:ELAN ) , Revolution Medicines ( NASDAQ:RVMD )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
